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Abstract
Background: While germline CHEK2 mutations have been linked to a moderately elevated cancer risk, to date, a
limited number of such mutations have been identified. Recently, we reported a germline nonsense mutation
(C283T; R95*), introducing an early stop-codon, in two Norwegian patients diagnosed with locally advanced
breast cancer. Both patients were resistant to anthracycline therapy, resembling what has been observed for
TP53 mutations.
Methods: In the present study, we screened a large population based sample, including 3748 non-cancer
individuals and 7081 incident cancer cases (breast cancer, n = 1717; prostate cancer n = 2501, lung cancer
n = 1331 and colorectal cancer n = 1532), for the distribution of CHEK2 R95*.
Results: We found that 12 individuals (0.11 %) carried the R95* variant: 4 non-cancer individuals (0.11 %), 4 breast
cancer cases (0.23 %), and 4 prostate cancer cases (0.16 %). Although the low number of observations precluded
formal statistical assessment, our data may indicate an elevated risk for breast (OR: 2.19, 95 % CI: 0.55–8.75) and
prostate cancer (OR: 1.5, 95 % CI: 0.36–6.00) associated with CHEK2 R95*. By mining international databanks, we
found no individuals carrying the R95* mutation, indicating it to be restricted to the Norwegian population.
Conclusion: We provide proof-of-concept that previously unknown CHEK2 germline mutations may be present in
certain populations. Notably, germline mutations in tumours are in general missed by contemporary massive
parallel sequencing strategies, since tumour mutations are usually filtered against the germline. The fact that the
CHEK2 R95* mutation may be associated with resistance to anthracyclines in cancer patients emphasizes its
possible clinical importance.
Background
Checkpoint kinase 2 (CHEK2) has a critical role as a
tumour suppressor, activating p53 in response to geno-
toxic stress. A limited number of germline point muta-
tions in CHEK2 have been identified. In general, these
are present at low frequencies and have moderate impact
on cancer risk: the most frequent and most studied
variant, the 1100delC truncation, occurs in approxi-
mately 1 % of Northern Europeans [1–3]. Unlike single
amino acid substitutions, the 1100delC truncation vari-
ant has been associated with an increased risk for cancer
of the breast and prostate [1, 3]. Also, a larger 5395 bp
germline deletion observed in individuals of Eastern
European descent, has been linked to increased risk of
breast cancer [1, 4, 5], and recently several germline
truncating CHEK2 mutations were linked to risk of
Non-Hodgkin Lymphoma [6]. Taken together, these, and
other data clearly indicates CHEK2 to be a multi-cancer
susceptibility gene, with truncating mutation being of
particular importance for some cancer types [7].
In a previous study, we found two unrelated patients
to harbour a germline C – T transition in position 283
of the coding region of CHEK2 (rs587781269; Fig. 1).
This transition introduced a novel translation stop at
codon 95 (CGA→TGA; R95*) causing a severely
truncated protein [8]. The mutant protein proved to be
non-functional both in terms of kinase activity and
dimerization in in vitro assays [8]. Importantly, both
patients carrying the R95* variant revealed primary
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resistance to anthracycline therapy [8], resembling what
we observed for patients with tumours harbouring
somatic TP53 mutations in the same study [8–10].
The aim of the present study was to determine the
CHEK2 R95* mutation incidence and potential influence
on cancer risk across the general population.
Methods
Study population
All samples (DNA from blood) analyzed (n = 10,830)
were obtained from the population-based Cohort of
Norway (CONOR) study [11]. Participants were from all
regions of Norway, but the majority (n = 4131) were
residents of Nord-Trøndelag County in Mid-Norway.
The mean age at sampling was 61.2 years (range 20.0–
93.6 years). Incident cancers were identified by linking
the identity of individuals to the Norwegian Cancer
Registry. We analyzed 1717 incident cases of breast can-
cer, 1532 colon cancers, 1331 lung cancers and 2501
prostate cancers, in addition to 3749 control individuals
without cancer. The 10,830 individuals are identical to
the sample set previously described [12]. One sample
failed analysis, thus, samples from 10,829 individuals
were used for data assessments. All sample donors pro-
vided written informed consent to anonymous genetic
testing for scientific purposes, and the study was ap-
proved by the Regional Committee for Ethics in Medical
Research (REK Midt-Norge).
CHEK2 R95* genotyping
All samples were genotyped for the CHEK2 R95* muta-
tion using a custom LightSNiP assay (TIB MOLBIOL
Syntheselabor GmbH, Berlin, Germany) on a LightCycler
480 II instrument (Roche, Basel, Switzerland). Reaction
mixes and thermocycling conditions were set according
to the manufacturer’s instructions
Results
In order to assess the frequency of the CHEK2 R95*
mutation in the general Norwegian population, we geno-
typed peripheral blood DNA from a previously described
[12] sample set (n = 10,829) extracted from the popula-
tion based CONOR biobank. The CHEK2 R95* mutation
was observed in four out of 3748 individuals without
any cancer diagnosis (0.11 %; Minor allele frequency
[MAF] 5.3 × 10−4; Table 1), in four out of 1717 breast
cancer patients (0.23 %), and in four out of 2501 prostate
cancer patients (0.16 %). In contrast, none out of 1331
lung cancer and none among 1532 colorectal cancer
patients harboured the mutation (Table 1). While the
low number of observations precluded any formal statis-
tical assessment of the role of R95* as a potential cancer
risk factor, our data may indicate an elevated risk for
breast (OR: 2.19, 95 % CI: 0.55–8.75) and prostate
cancer (OR: 1.5, 95 % CI: 0.36–6.00) among mutation
carriers. Supporting this, we found the age at diagnosis
among the breast and prostate cancer patients to be
Fig. 1 Schematic representation of the CHEK2 gene with details on the flanking region of the R95* mutation (in bold; C = reference allele,
T = alternative allele)
Table 1 Frequency of the CHEK2 R95* germline mutation in the Norwegian population
Individuals/patients R95*-carriersan Wild-type n Total MAF
Non-cancer individuals 4 3744 3748 5.3 × 10−4
Cancer patients 8 7073 7081 5.6 × 10−4
Breast cancer 4 1713 1717 1.2 × 10−3
Prostate cancer 4 2497 2501 8.0 × 10−4
Lung cancer 0 1331 1331 0
Colorectal cancer 0 1532 1532 0
Total 12 10,817 10,829 5.5 × 10−4
aAll R95* carriers were heterozygous
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slightly lower among the R95* carriers than among the
CHEK2 wild-type patients (Table 2).
We performed data mining in order to assess whether the
R95* mutation was restricted to certain geographical areas:
We searched the 1000 genomes project phase 3, providing
genomic data for 2439 individuals of different ethnic origin
including several Caucasian sub-populations [13]: none of
them harboured the R95* mutation, indicating that the vari-
ant may be restricted to the Norwegian population. The
CONOR biobank contains samples collected from individ-
uals living in distinct parts of Norway; thus, some regions
are represented in particular. Accessing information about
the county of residence for each individual donor, we found
11 out of 12 individuals harbouring the R95* mutation to be
residents of the Nord-Trøndelag County in Mid-Norway
(consisting of about 2.6 % of the Norwegian population and
contributing 4131 individuals to our cohort), contrasting one
R95* mutation carrier out of 6698 participants living in other
parts of Norway, (difference in incidence: p= 1.9 × 10−4).
Restricting the association estimates to residents of Nord-
Trøndelag did not have any major impact on the results
(OR: 1.49, 95 % CI: 0.33–6.66 for breast cancer and OR:
1.32, 95 % CI: 0.33–5.30 for prostate cancer).
Discussion
In the present study, we screened a large population
based cohort, and found the prevalence of the CHEK2
R95* mutation to be low and restricted to Norway.
Despite the low frequencies of the individual mutations,
precluding proper statistical assessment of the odd ratios,
germline CHEK2 mutations seem to be the underlying
cause of hereditable cancer syndromes in some families
[1, 2, 14]. To date, the most studied CHEK2 germline
mutation is the 1100delC variant, which has a relatively
high frequency in the Caucasian population: approxi-
mately 1 % of healthy individuals are estimated to carry
the 1100delC-variant [1–3]. Contrasting the risk assess-
ments of single amino acid substitutions of the CHEK2, it
has been estimated that the 1100delC-variant confers a
two-fold elevated risk of both breast cancer [3] and pros-
tate cancer [1]. Further, another deletion variant in East-
ern Europe (5395 bp deletion) has also been linked to
increased breast cancer risk [1, 4, 5] and several germline
truncating variants have been linked to Non-Hodgkin
lymphoma [6].
Recently, another novel germline CHEK2 mutation,
Y390C, was reported [15]. Interestingly, this mutation
was associated with elevated risk for breast cancer but
also resistance towards anthracyclines in vitro. In an
earlier study, we also reported another truncating
CHEK2 mutation, (ins1368A), to be associated with
resistance to anthracycline therapy in a breast cancer
patient [16]; thus, all these three mutations (R95*, Y390C
and ins1368A) seem associated with defect DNA damage
signaling leading to drug resistance. Notably, this
contrasts some of the previously reported missense muta-
tions (e.g. I157T and I364T) that seem to retain a wild-
type kinase activity [8]. While we may not draw any final
conclusion due to a limited number of observations, our
data are consistent with the hypothesis [1–5] that certain
CHEK2 mutations (as opposed to most missense muta-
tions) may be associated with elevated cancer risk and,
more importantly, resistance towards DNA damaging
agents used in cancer therapy [9].
Our findings underline some issues that need to be
taken into consideration. Firstly, most likely, there are
additional germline pathogenic CHEK2 mutations, not yet
discovered. These mutations are likely to be rare and may
be distributed across restricted geographical areas. Sec-
ondly, such mutations may be of severe clinical import-
ance, e.g. have an impact on cancer risk and sensitivity to
chemotherapy [8–10, 16]. Thirdly, as massive parallel
sequencing strategies are increasingly being used, not only
for research purposes, but also to guide treatment deci-
sions, it is important to note that such germline mutations
are likely to be missed by contemporary practice where
somatic mutations are being filtered against the germline
to remove non-functional SNPs.
Conclusion
In conclusion, potential germline mutations affecting the
CHEK2 gene should be taken into consideration when ex-
ploring the genetic mechanisms of drug resistance among
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Table 2 Age at cancer diagnosis
Average age at cancer diagnosis
Diagnosis R95*-carriers Wild-type Total
Breast cancer 55.75 60.36 60.35
Prostate cancer 69.75 71.72 71.72
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